PRL3-zumab, a first-in-class humanized antibody for cancer therapy

Novel, tumor-specific drugs are urgently needed for a breakthrough in cancer therapy. Herein, we generated a first-in-class humanized antibody (PRL3-zumab) against PRL-3, an intracellular tumor-associated phosphatase upregulated in multiple human cancers, for unconventional cancer immunotherapies. W...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:JCI Insight
Main Authors: Thura, Min, Al-Aidaroos, Abdul Qader Omer, Yong, Wei Peng, Kono, Koji, Gupta, Abhishek, Lin, You Bin, Mimura, Kousaku, Thiery, Jean Paul, Goh, Boon Cher, Tan, Patrick, Soo, Ross, Hong, Cheng William, Wang, Lingzhi, Lin, Suling Joyce, Chen, Elya, Rha, Sun Young, Chung, Hyun Cheol, Li, Jie, Nandi, Sayantani, Yuen, Hiu Fung, Zhang, Shu-Dong, Guan, Yeoh Khay, So, Jimmy, Zeng, Qi
Formato: Artigo
Idioma:Inglês
Publicado em: American Society for Clinical Investigation 2016
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5033845/
https://ncbi.nlm.nih.gov/pubmed/27699276
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/jci.insight.87607
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados